Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases
Pharmacological Reports · 2026
DOI: 10.1007/s43440-026-00829-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Reports, 2026. Verfasst von Brígida R Pinho und 5 weiteren Autor:innen. Beteiligte Einrichtung: UCIBIO Applied Molecular Biosciences Unit, Mitochondria and Neurobiology Lab, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal. Hauptthemen laut MEDLINE: Mitophagy, Mitochondria, Mitochondrial Diseases, Mitochondrial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade do Porto.
Abstract (Originalsprache)
Background
Mitochondrial DNA (mtDNA) diseases are heterogeneous and lack effective treatments. Their severity correlates with mutant mtDNA load. Mitophagy degrades dysfunctional mitochondria, contributing to a healthy mitochondrial pool. USP30, a mitochondrial deubiquitinase, limits mitophagy by removing the ubiquitin tagging mitochondria for degradation. We investigated whether inhibiting USP30 could enhance mitophagy and reduce mutant mtDNA load in a heteroplasmic mitochondrial disease.
Methods
Cybrids cells harboring mutant m.8993T > G mtDNA - common cause of NARP syndrome and maternally inherited Leigh syndrome (MILS) - were treated with USP30 inhibitor MF-094 under glycolytic and oxidative phosphorylation conditions. On-target activity of MF-094 was assessed by mitochondrial ubiquitination (western-blot) and mitolysosome formation (microscopy). The mutation’s effects were investigated on cell proliferation and metabolism (respirometry and ATP levels). The impact of MF-094 on mutant mtDNA load and mtDNA copy number was quantified by PCR.
Results
Comparing with control cells (0% mutant mtDNA), cells with mutant mtDNA exhibited reduced proliferation and ATP levels under oxidative phosphorylation conditions; and reduced oxygen consumption, increased extracellular acidification, and sustained resazurin metabolism after mitochondrial inhibition under glycolytic conditions. MF-094 induced mitophagy via increased mitolysosome formation. Mechanistically, MF-094 showed on-target effects, increasing mitochondrial ubiquitination. However, chronic treatment (3–6 weeks) evoked only a small (5%) non-significant reduction in mutant mtDNA load.
Conclusions
Despite inducing mitophagy, the USP30 inhibitor MF-094 showed little potential to manage m.8993T > G related diseases, as it did not significantly reduce the load of this NARP/MILS causing mtDNA mutation. These results highlight the complexity of mutant mtDNA management and the need for innovative strategies for these disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCIBIO Applied Molecular Biosciences Unit, Mitochondria and Neurobiology Lab, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal.
- Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal.
- Department of Cell and Developmental Biology, University College London, London, UK.
- Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Porto, Portugal.
- UCIBIO Applied Molecular Biosciences Unit, Mitochondria and Neurobiology Lab, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal. jorgemao@ff.up.pt.
- Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Porto, 4500-313, Portugal. jorgemao@ff.up.pt.
Förderung
- Universidade do Porto
Zitieren
APA
Pinho, B. R., Martins, V., Chacko, A. R., Nogueira, C., Duchen, M. R., & Oliveira, J. M. A. (2026). Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases. Pharmacological Reports. https://doi.org/10.1007/s43440-026-00829-7
Vancouver
Pinho BR, Martins V, Chacko AR, Nogueira C, Duchen MR, Oliveira JMA. Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases. Pharmacological Reports. 2026. doi:10.1007/s43440-026-00829-7
BibTeX
@article{Pinho2026,
author = {Pinho, Brígida R and Martins, Vasco and Chacko, Anitta R and Nogueira, Célia and Duchen, Michael R and Oliveira, Jorge M A},
title = {Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases},
journal = {Pharmacological Reports},
year = {2026},
doi = {10.1007/s43440-026-00829-7}
}
EUVIMED